Patent ID: 9532970
Date: 2017-01-03
CPC Classifications: A61K,A61P,C07C

Claim:
1. A method of treating or preventing pulmonary edema or exercise-induced pulmonary hemorrhage (EIPH), comprising administering to a subject in need thereof a composition comprising about 0.01 micrograms per kilogram of body weight to about 100 milligrams per kilogram of body weight of L-sulforaphane (LSF), an LSF derived and/or substituted compound, and/or an LSF analogue, wherein the LSF, LSF derived and/or substituted compound, and/or an LSF analogue has the following formula: wherein R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted acyl, ORa, SRa, SORa, SO2Ra, OSO2Ra, OSO3Ra, NO2, NHRa, N(Ra)2, N(Ra)CORa, N(CORa)2, N(Ra)C(═NRa)N(Ra)Ra, CN, halogen, CORa, COORa, OCORa, OCOORa, OCONHRa, OCON(Ra)2, CONHRa, CON(Ra)2, CON(Ra)ORa, CON(Ra)SO2Ra, PO(ORa)2, PO(ORa)Ra, PO(ORa)(N(Ra)Ra) and amino acid ester having inhibitory efficacy against the LSD1 protein; and further wherein each of the Ra groups is independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclyl, substituted or unsubstituted acyl; and further wherein each of the substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heterocycyl, and/or acyl groups are C1-28; and hydroxytyrosol, oleuropein, N-acetylcysteine, L-proline, glycine, and taurine.